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Background: High-grade serous ovarian cancers are a distinct histological subtype of ovarian cancer often
characterised by a dysfunctional BRCA/Fanconi anaemia (BRCA/FA) pathway, which is critical to the homologous
recombination DNA repair machinery. An impaired BRCA/FA pathway sensitises tumours to the treatment with
DNA cross-linking agents and to PARP inhibitors. The vast majority of inactivating mutations in the BRCA/FA
pathway are in the BRCA1 and BRCA2 genes and occur predominantly in high-grade serous cancer. Another
member of the BRCA/FA pathway, PALB2 (FANCN), was reported to have been inactivated by DNA methylation in
some sporadic ovarian cancers. We therefore sought to investigate the role of PALB2 methylation in high-grade
serous ovarian cancers.
Finding: PALB2 methylation was investigated in 92 high-grade serous ovarian cancer samples using methylation-
sensitive high-resolution melting analysis. DNA methylation of PALB2 was not detected in any of the ovarian cancer
samples investigated.
Conclusion: Epigenetic silencing by DNA methylation of PALB2 is not a common event in high-grade serous
ovarian cancers.
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Ovarian cancer comprises several broad groups of distinct
diseases [1]. The largest group are high-grade serous
ovarian cancers, of which a substantial proportion are
characterised by an impaired BRCA/Fanconi anaemia
(BRCA/FA) pathway [2,3]. The BRCA/FA pathway is a
key part of the homologous recombination DNA repair
machinery and includes the BRCA1 and BRCA2 genes as
well as members of the Fanconi anaemia complementa-
tion group. The inactivation of the BRCA/FA pathway is
associated with an increased sensitivity of cancerous cells
to DNA cross-linking agents and to PARP inhibitors [4,5].
The vast majority of inactivating mutations that occur
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[2]. The protein product of the Fanconi anaemia gene
PALB2 (FANCN) serves as a bridge between BRCA1 and
BRCA2 [6]. Mutations of PALB2 have been associated
with familial breast cancer and pancreatic cancer [6].
The occurrence of PALB2 mutations in ovarian cancer
has been less studied but is probably rare [7,8].
Aberrant DNA methylation is an alternative mecha-
nism for PALB2 inactivation. PALB2 methylation has
been reported in familial and sporadic breast cancer
cases as well as in sporadic ovarian cancer samples [9].
In the sporadic ovarian cancer samples, PALB2 methyla-
tion was reported to occur at a frequency of approximately
8%. However, the number of sporadic ovarian cancer cases
investigated was quite small (53 samples) and consisted of
different histological subtypes, grades and stages.
We sought to investigate aberrant PALB2 methyla-
tion in a large number of high-grade serous ovarian can-
cers using methylation-sensitive high-resolution melting
(MS-HRM) [10]. MS-HRM uses methylation-independent
PCR primers which allow the amplification of bisulfite-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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status. The analysis is based on the different melting be-
haviour of unmethylated and methylated templates after
PCR amplification. The melting behaviour of an individual
sample is visualised as a melting profile, which can be
compared to melting profiles of DNA methylation stan-
dards and allows the estimation of the amount of methyla-
tion semi-quantitatively [11].
Ninety-two unselected high-grade serous ovarian can-
cer samples from The Australian Ovarian Cancer Study
(AOCS) were used in this study. AOCS is a population-
based case control study where newly diagnosed cases of
ovarian, peritoneal and fallopian tube tumours were pro-
spectively ascertained from major treatment centres and
state-based cancer registries around Australia between
January 2002 and June 2006, as previously described
[3,12]. DNA was extracted from the fresh-frozen primary
tumour samples using the DNeasy Blood and Tissue Kit
(Qiagen, Hilden, Germany). Primary tissue sample as-
sessed as being of low tumour content by pathological
review was needle macro-dissected before DNA extrac-
tion. DNA concentration and quality was measured using
the NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies, Thermo Fisher Scientific, Wilmington, DE).
The use of the DNA has been approved by the Human
Research Ethics Committee at the Peter MacCallum
Cancer Centre. Fully methylated human control DNA was
obtained commercially (Millipore, Billerica, MA). Control
DNAs from the peripheral blood of normal individuals
and the HL-60 cell line were extracted by using the
QIAamp DNA Blood Mini Kit (Qiagen) according to
the manufacturer’s instructions.
For bisulfite modification, 200 ng of DNA extracted
from the high-grade serous ovarian cancer samples and
500 ng of the control DNAs were bisulfite modified
using the EpiTect Bisulfite Kit (Qiagen) according to the
manufacturer’s instructions. The bisulfite-modified DNA
from the high-grade serous ovarian cancer samples was
eluted twice in a final volume of 40 μL (50 μL for the
control DNAs) of the supplied elution buffer, to give a
theoretical concentration of 5 ng/μL (10 ng/μL for the
control DNAs) presuming no loss of DNA during bisul-
fite modification.Figure 1 Genomic positions of the PCR amplicons used in the Potapo
PALB2 in the UCSC Genome Browser (GRCh37/hg19). The region invest
Potapova study [9].PALB2 and RASSF1A methylation was investigated by
MS-HRM. DNA methylation standard series were prepared
by diluting the bisulfite-modified fully methylated control
DNA in bisulfite-modified unmethylated control DNA from
peripheral blood for the analysis of PALB2 methylation, and
from HL-60 for the analysis of RASSF1A methylation,
respectively. The amount of PCR amplifiable templates of
the fully methylated and unmethylated control DNAs was
normalised prior to dilution as previously described [13].
The DNA methylation standard series comprised 100%,
50%, 25%, 10%, and 0% of methylated control DNA. MS-
HRM was performed on a Rotor-Gene 6000 (Corbett,
Sydney, Australia). Each sample and each DNA methylation
standard was run in duplicate, while the genomic DNA
control and the no template control were run only once.
The PCR primer sequences for the PALB2 methylation
analysis are: 50-TTTTCGGTTTAGGGTTAATTGGGTT-30
(forward primer) and 50-CACCTTTTCCTTCTCCTCAC
AACTAAA-30 (reverse primer). The PCR amplicon is
135 bp in size and corresponds to GenBank accession
number AC008870.8, nucleotides 68,324 to 68,458 (UCSC
Genome Browser: chr16: 23,652,428 to 23,652,562;
GRCh37/hg19) (Figure 1). The amplicon contains 10 CpG
dinucleotides and a G/A single-nucleotide polymorphism
(rs8053188) between the primers.
PCR was performed in 0.1 mL tubes with a final
reaction volume of 20 μL containing 200 nmol/L of
the forward primer, 400 nmol/L of the reverse primer,
200 μmol/L of each dNTP, 5 μmol/L SYTO 9 (Life
Technologies, Carlsbad, CA), 3.5 mmol/L MgCl2, 0.5U
HotStarTaq DNA polymerase in its supplied buffer (1X)
(Qiagen) and 5 ng (10 ng for the DNA methylation
standard series) of bisulfite-modified DNA. PCR amplifi-
cation was performed with one cycle of 95°C for 15 min,
50 cycles of 95°C for 20 s, 62°C for 20 s and 72°C for
30 s. This was immediately followed by a hold at 95°C
for 1 min, 70°C for 1.5 min and a HRM step from 70 to
95°C rising at 0.2°C per second, and holding for 1 s after
each stepwise increment. RASSF1A methylation analysis
was performed as previously described [14] with an al-
tered PCR amplification profile: one cycle of 95°C for
15 min, 55 cycles of 95°C for 10 s, 65°C for 20 s and
72°C for 30 s. This was immediately followed by a holdva study and in this study respectively, relative to exon 1 of
igated in this study partially overlaps with the region analysed in the
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from 65 to 95°C rising at 0.2°C per second, and holding
for 1 s after each stepwise increment.
The 92 high-grade serous ovarian cancer samples were
investigated for aberrant PALB2 methylation in exon 1
using MS-HRM. DNA methylation was not detectable in
any of the high-grade serous ovarian cancer samples
(Figure 2). To ensure that methylation would be detec-
ted if present, the samples were also tested for RASSF1A
methylation which has been previously reported in high-
grade serous ovarian cancer [15]. RASSF1A methylation
was seen at various levels in a large proportion of the
samples: 24 samples (26%) had no methylation, 46 sam-
ples (50%) had less than 10% methylation and 22 samples
(24%) had methylation levels ranging from 10% to 90%.
Potapova et al. reported methylation of a region in
exon 1 of PALB2 in breast and ovarian cancers [9].
Quantitative methylation-specific PCR was used to detect
aberrant PALB2 methylation. DNA methylation of the
methylation-positive samples was subsequently confirmed
by direct bisulfite sequencing. The region investigated by
MS-HRM partially overlaps with the above region and
contains the two CpG dinucleotides of the reverse
methylation-specific PCR (MSP) primer used in the
previous study (Figure 1). A positive MSP result can not
be obtained without one or both of those CpG dinucleo-
tides being methylated. Thus our results have not been
compromised by analysing an incompletely overlapping
region to that previously analysed, which is a necessary
consequence of the different PCR primer design principles
for the two assays.
MS-HRM is a reliable and sensitive methodology
which is well suited for the detection of homogeneousFigure 2 Melting profiles of selected high-grade serous ovarian cance
methylation analysis. The melting profiles were partly smoothened by ap
software. Melting profiles for fully methylated (100%), 50%, 10% and unme
red, turquoise, black, green and blue curves. Tm plots (negative first derivat
corresponding difference plots are shown in the right panel, respectively. In
are chosen as a baseline and the relative differences in melting profiles of
serous ovarian cancer DNAs (blue curves) are unmethylated for PALB2 as ca
(green curves).and heterogeneous methylation at gene-specific loci
[16,17]. The PALB2 MS-HRM assay conditions have
been optimised and show sensitivity for the reliable de-
tection of methylated epialleles down to below 10%
(Figure 2). The sensitivity of the MS-HRM assay to
detect aberrant DNA methylation is sufficient as it was
estimated that some samples showed less than 20% of
methylated epialleles [9].
Interestingly, all the four sporadic ovarian cancer cases
that were found to be positive for PALB2 methylation in
the Potapova study were clear cell carcinomas, or sho-
wed foci of clear cell carcinoma [9]. Clear cell ovarian
tumours have been compared to renal cell tumours in
the past [18], and are now believed to be not only mor-
phologically [19], but molecularly distinct when com-
pared to high-grade serous and high-grade endometrioid
ovarian cancers [20,21].
The lack of PALB2 methylation-positive samples in
our study might be explained by the fact that we have
investigated high-grade serous ovarian cancer cases only,
which presumably evolve via a different tumorigenic path-
way of development than clear cell carcinomas [20]. How-
ever, because high-grade serous ovarian cancer is driven
by disrupted homologous recombination, we may have
reasonably expected to observe PALB2 methylation as a
method of pathway disruption.
In conclusion, we showed that epigenetic silencing by
DNA methylation is an unlikely mechanism for PALB2
inactivation in high-grade serous ovarian cancers. Our
findings and those of The Cancer Genome Atlas Re-
search Network [2] now challenge the contribution of
PALB2 methylation to the dysfunction of the BRCA/FA
pathway in this histological subtype of ovarian cancer.r samples obtained from MS-HRM experiments for PALB2
plying a light digital filter available in the Rotor-Gene 6000 analysis
thylated (0%) standards as well as the tumour samples are shown as
ive of the melting curves) are shown in the left panel and the
difference plots, the melting profiles of the fully methylated standard
all other samples are plotted relative to this baseline. The high-grade
n be seen by their superimposition on the unmethylated standard
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